Mon. Jun 27th, 2022
From NewsMax

A targeted oral drug combination by Novartis won U.S. approval for use in a wide range of advanced solid tumors that are driven by a certain genetic contributor, widening the use of a novel treatment approach that is known as tumor agnostic. The Food and Drug Administration…
Read More

By

Leave a Reply

Your email address will not be published.